Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants

Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2011-08, Vol.9 (8), p.700-704.e1
Hauptverfasser: O'Leary, Jacqueline G, Landaverde, Carmen, Jennings, Linda, Goldstein, Robert M, Davis, Gary L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 704.e1
container_issue 8
container_start_page 700
container_title Clinical gastroenterology and hepatology
container_volume 9
creator O'Leary, Jacqueline G
Landaverde, Carmen
Jennings, Linda
Goldstein, Robert M
Davis, Gary L
description Background & Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores >15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.
doi_str_mv 10.1016/j.cgh.2011.04.007
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4408909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1542356511003879</els_id><sourcerecordid>879104959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</originalsourceid><addsrcrecordid>eNp9Uk2P0zAQjRCIXRZ-ABfkG6eGceLUsZBWqiKgSBUgtoij5TjT1t00ztpJpf57JmpZAQcu_pDfe-M3b5LkNYeUA5-_26d2u0sz4DwFkQLIJ8k1L0Q2k5KLp5dzXsyLq-RFjHuATAklnydXGS8kiDK_TsZvZnDYDZH9dMOOfVncLZnpGlaFUz_4LXbOssqFsPPRRbYIyFYYI1u5e2xPbL0zHS0-4pm-xJ7kBkJWbPDsO1p0R6LQEtg6mC72raFiL5NnG9NGfHXZb5IfHz-sq-Vs9fXT52qxmtkCimHGoWwyqOebUiglFVpj6lKUhcoV3a2Q0tSN5RLAcFtkWV6LjJN3m2dKljXkN8ntWbcf6wM2lowG0-o-uIMJJ-2N03-_dG6nt_6ohYBSgSKBtxeB4B9GjIM-uGixJRfox6hLqTgIVUxIfkba4GMMuHmswkFPaem9prT0lJYGoSkt4rz583uPjN_xEOD9GYDUpKPDoKOltCw2LqAddOPdf-Vv_2Hb1lGgpr3HE8a9H0NH3ddcx0yDvpvGZZoWzgFycpb_AmrPujk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879104959</pqid></control><display><type>article</type><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</creator><creatorcontrib>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</creatorcontrib><description>Background &amp; Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores &gt;15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2011.04.007</identifier><identifier>PMID: 21570483</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cirrhosis ; Disease Progression ; Fatty Liver ; Fatty Liver - complications ; Fatty Liver - pathology ; Female ; Follow-Up Studies ; Gastroenterology and Hepatology ; Hepatitis C ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - pathology ; Hepatitis, Chronic - complications ; Hepatitis, Chronic - pathology ; Humans ; Liver Cirrhosis - complications ; Liver Cirrhosis - pathology ; Liver Failure - epidemiology ; Liver Failure - surgery ; Liver Transplantation ; Male ; Middle Aged ; NASH ; Non-alcoholic Fatty Liver Disease ; Severity of Illness Index</subject><ispartof>Clinical gastroenterology and hepatology, 2011-08, Vol.9 (8), p.700-704.e1</ispartof><rights>AGA Institute</rights><rights>2011 AGA Institute</rights><rights>Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</citedby><cites>FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2011.04.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21570483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Leary, Jacqueline G</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><creatorcontrib>Jennings, Linda</creatorcontrib><creatorcontrib>Goldstein, Robert M</creatorcontrib><creatorcontrib>Davis, Gary L</creatorcontrib><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background &amp; Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores &gt;15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</description><subject>Cirrhosis</subject><subject>Disease Progression</subject><subject>Fatty Liver</subject><subject>Fatty Liver - complications</subject><subject>Fatty Liver - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>Hepatitis, Chronic - complications</subject><subject>Hepatitis, Chronic - pathology</subject><subject>Humans</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Failure - epidemiology</subject><subject>Liver Failure - surgery</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NASH</subject><subject>Non-alcoholic Fatty Liver Disease</subject><subject>Severity of Illness Index</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uk2P0zAQjRCIXRZ-ABfkG6eGceLUsZBWqiKgSBUgtoij5TjT1t00ztpJpf57JmpZAQcu_pDfe-M3b5LkNYeUA5-_26d2u0sz4DwFkQLIJ8k1L0Q2k5KLp5dzXsyLq-RFjHuATAklnydXGS8kiDK_TsZvZnDYDZH9dMOOfVncLZnpGlaFUz_4LXbOssqFsPPRRbYIyFYYI1u5e2xPbL0zHS0-4pm-xJ7kBkJWbPDsO1p0R6LQEtg6mC72raFiL5NnG9NGfHXZb5IfHz-sq-Vs9fXT52qxmtkCimHGoWwyqOebUiglFVpj6lKUhcoV3a2Q0tSN5RLAcFtkWV6LjJN3m2dKljXkN8ntWbcf6wM2lowG0-o-uIMJJ-2N03-_dG6nt_6ohYBSgSKBtxeB4B9GjIM-uGixJRfox6hLqTgIVUxIfkba4GMMuHmswkFPaem9prT0lJYGoSkt4rz583uPjN_xEOD9GYDUpKPDoKOltCw2LqAddOPdf-Vv_2Hb1lGgpr3HE8a9H0NH3ddcx0yDvpvGZZoWzgFycpb_AmrPujk</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>O'Leary, Jacqueline G</creator><creator>Landaverde, Carmen</creator><creator>Jennings, Linda</creator><creator>Goldstein, Robert M</creator><creator>Davis, Gary L</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110801</creationdate><title>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</title><author>O'Leary, Jacqueline G ; Landaverde, Carmen ; Jennings, Linda ; Goldstein, Robert M ; Davis, Gary L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-108d20b6f849979ecaab8485939997c477abdc1700a1c5223b421771c32978b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Cirrhosis</topic><topic>Disease Progression</topic><topic>Fatty Liver</topic><topic>Fatty Liver - complications</topic><topic>Fatty Liver - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>Hepatitis, Chronic - complications</topic><topic>Hepatitis, Chronic - pathology</topic><topic>Humans</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Failure - epidemiology</topic><topic>Liver Failure - surgery</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NASH</topic><topic>Non-alcoholic Fatty Liver Disease</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Leary, Jacqueline G</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><creatorcontrib>Jennings, Linda</creatorcontrib><creatorcontrib>Goldstein, Robert M</creatorcontrib><creatorcontrib>Davis, Gary L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Leary, Jacqueline G</au><au>Landaverde, Carmen</au><au>Jennings, Linda</au><au>Goldstein, Robert M</au><au>Davis, Gary L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>9</volume><issue>8</issue><spage>700</spage><epage>704.e1</epage><pages>700-704.e1</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background &amp; Aims Many patients with cryptogenic cirrhosis (CC) have other conditions associated with nonalcoholic steatohepatitis (NASH) that put them at risk for complications that preclude orthotopic liver transplantation (OLT). Methods We followed all patients with NASH and CC who were evaluated for OLT (n = 218) at Baylor Simmons Transplant Institute between March 2002 and May 2008. Data were compared with those from patients evaluated for OLT because of hepatitis C virus (HCV)-associated cirrhosis (n = 646). Results Patients with NASH and CC were older, more likely to be female, had a higher body mass index, and a greater prevalence of diabetes and hypertension, compared with patients with HCV-associated cirrhosis, but the 2 groups had similar model for end-stage liver disease (MELD) scores. NASH and CC in patients with MELD scores ≤15 were less likely to progress; these patients were less likely to receive OLT and more likely to die or be taken off the wait list because they were too sick, compared with patients with HCV-associated cirrhosis. The median progression rate among patients with NASH and CC was 1.3 MELD points per year versus 3.2 MELD points per year for the HCV group ( P = .003). Among patients with MELD scores &gt;15, there were no differences among groups in percentage that received transplants or rate of MELD score progression. Hepatocellular carcinoma occurred in 2.7% of patients with NASH and CC per year, compared with 4.7% per year among those with HCV-associated cirrhosis. Conclusions Patients with NASH and CC and low MELD scores have slower disease progression than patients with HCV-associated cirrhosis and are less likely to receive OLT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21570483</pmid><doi>10.1016/j.cgh.2011.04.007</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2011-08, Vol.9 (8), p.700-704.e1
issn 1542-3565
1542-7714
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4408909
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Cirrhosis
Disease Progression
Fatty Liver
Fatty Liver - complications
Fatty Liver - pathology
Female
Follow-Up Studies
Gastroenterology and Hepatology
Hepatitis C
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - pathology
Hepatitis, Chronic - complications
Hepatitis, Chronic - pathology
Humans
Liver Cirrhosis - complications
Liver Cirrhosis - pathology
Liver Failure - epidemiology
Liver Failure - surgery
Liver Transplantation
Male
Middle Aged
NASH
Non-alcoholic Fatty Liver Disease
Severity of Illness Index
title Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T15%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patients%20With%20NASH%20and%20Cryptogenic%20Cirrhosis%20Are%20Less%20Likely%20Than%20Those%20With%20Hepatitis%20C%20to%20Receive%20Liver%20Transplants&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=O'Leary,%20Jacqueline%20G&rft.date=2011-08-01&rft.volume=9&rft.issue=8&rft.spage=700&rft.epage=704.e1&rft.pages=700-704.e1&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2011.04.007&rft_dat=%3Cproquest_pubme%3E879104959%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879104959&rft_id=info:pmid/21570483&rft_els_id=1_s2_0_S1542356511003879&rfr_iscdi=true